Biotech, regional banks ripe for acquisition in 2023 -CIO

STORY: Continued Mahn, "Generally, where do... cures and therapeutics come from? Well, they come from smaller cap biotech companies.... It's the large cap pharmaceutical companies, on the other hand, that are flush in cash on their balance sheets, that are seeing their profit margins being squeezed by Congress asking them to push down their drug prices, and that have a large number of large revenue-producing drugs coming off patent and now being subject to generic pricing. So where are those large cap pharmaceutical companies going to turn to replace all that lost revenue? We think they're gonna turn to the acquisitions of these smaller cap biotech companies...."